New Risk • May 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Reported Earnings • May 21
Full year 2026 earnings released: EPS: ₹6.22 (vs ₹0.21 in FY 2025) Full year 2026 results: EPS: ₹6.22 (up from ₹0.21 in FY 2025). Revenue: ₹29.9b (up 10% from FY 2025). Net income: ₹974.5m (up ₹942.1m from FY 2025). Profit margin: 3.3% (up from 0.1% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹211, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 33x in the Life Sciences industry in India. Total returns to shareholders of 85% over the past three years. Announcement • May 14
Dishman Carbogen Amcis Limited to Report Q4, 2026 Results on May 19, 2026 Dishman Carbogen Amcis Limited announced that they will report Q4, 2026 results on May 19, 2026 Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹151, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 15% over the past three years. Reported Earnings • Feb 04
Third quarter 2026 earnings released: ₹0.83 loss per share (vs ₹0.30 profit in 3Q 2025) Third quarter 2026 results: ₹0.83 loss per share (down from ₹0.30 profit in 3Q 2025). Revenue: ₹7.26b (up 6.5% from 3Q 2025). Net loss: ₹129.7m (down 380% from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth. Announcement • Jan 29
Dishman Carbogen Amcis Limited to Report Q3, 2026 Results on Feb 03, 2026 Dishman Carbogen Amcis Limited announced that they will report Q3, 2026 results on Feb 03, 2026 Valuation Update With 7 Day Price Move • Jan 23
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹209, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 148% over the past three years. Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹265, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 32x in the Life Sciences industry in India. Total returns to shareholders of 194% over the past three years. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹247, the stock trades at a trailing P/E ratio of 28.4x. Average trailing P/E is 39x in the Life Sciences industry in India. Total returns to shareholders of 125% over the past three years. Reported Earnings • Nov 05
Second quarter 2026 earnings released: EPS: ₹4.16 (vs ₹2.11 in 2Q 2025) Second quarter 2026 results: EPS: ₹4.16 (up from ₹2.11 in 2Q 2025). Revenue: ₹6.61b (down 16% from 2Q 2025). Net income: ₹652.7m (up 97% from 2Q 2025). Profit margin: 9.9% (up from 4.2% in 2Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Oct 31
Dishman Carbogen Amcis Limited to Report Q2, 2026 Results on Nov 04, 2025 Dishman Carbogen Amcis Limited announced that they will report Q2, 2026 results on Nov 04, 2025 Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹314, the stock trades at a trailing P/E ratio of 47.3x. Average trailing P/E is 51x in the Life Sciences industry in India. Total returns to shareholders of 236% over the past three years. Announcement • Aug 29
Dishman Carbogen Amcis Limited, Annual General Meeting, Sep 29, 2025 Dishman Carbogen Amcis Limited, Annual General Meeting, Sep 29, 2025, at 15:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2026 earnings released: EPS: ₹1.49 (vs ₹4.95 loss in 1Q 2025) First quarter 2026 results: EPS: ₹1.49 (up from ₹4.95 loss in 1Q 2025). Revenue: ₹7.33b (up 40% from 1Q 2025). Net income: ₹234.1m (up ₹1.01b from 1Q 2025). Profit margin: 3.2% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 30% per year, which means it is well ahead of earnings. Announcement • Aug 09
Dishman Carbogen Amcis Limited to Report Q1, 2026 Results on Aug 12, 2025 Dishman Carbogen Amcis Limited announced that they will report Q1, 2026 results on Aug 12, 2025 New Risk • Jun 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Large one-off items impacting financial results. Reported Earnings • May 22
Full year 2025 earnings released: EPS: ₹0.21 (vs ₹9.79 loss in FY 2024) Full year 2025 results: EPS: ₹0.21 (up from ₹9.79 loss in FY 2024). Revenue: ₹27.3b (up 4.5% from FY 2024). Net income: ₹32.4m (up ₹1.57b from FY 2024). Profit margin: 0.1% (up from net loss in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance. Announcement • May 16
Dishman Carbogen Amcis Limited to Report Q4, 2025 Results on May 21, 2025 Dishman Carbogen Amcis Limited announced that they will report Q4, 2025 results on May 21, 2025 New Risk • Apr 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 55% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). Board Change • Apr 08
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Kulin Shah was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 13
Third quarter 2025 earnings released: EPS: ₹0.30 (vs ₹3.80 loss in 3Q 2024) Third quarter 2025 results: EPS: ₹0.30 (up from ₹3.80 loss in 3Q 2024). Revenue: ₹6.88b (up 5.7% from 3Q 2024). Net income: ₹46.3m (up ₹642.6m from 3Q 2024). Profit margin: 0.7% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. Announcement • Feb 08
Dishman Carbogen Amcis Limited to Report Q3, 2025 Results on Feb 12, 2025 Dishman Carbogen Amcis Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Announcement • Feb 04
Dishman Carbogen Amcis Limited Approves Appointment of Kulin N. Shah as an Independent Director Dishman Carbogen Amcis Limited approved the appointment of Mr. Kulin N. Shah as an Independent Director for a first term of five consecutive years by Postal ballot. Announcement • Dec 15
Dishman Carbogen Amcis Limited Announces Cessation of Subir Kumar Das as Independent Director, Effective 15 December, 2024 Dishman Carbogen Amcis Limited announced that the second and final term of Mr. Subir Kumar Das as an Independent Director has been completing on 14 December, 2024 and consequently cease to be Director of the Company with effect from 15 December, 2024. Reported Earnings • Nov 14
Second quarter 2025 earnings released: EPS: ₹2.11 (vs ₹2.61 loss in 2Q 2024) Second quarter 2025 results: EPS: ₹2.11 (up from ₹2.61 loss in 2Q 2024). Revenue: ₹7.96b (up 36% from 2Q 2024). Net income: ₹330.9m (up ₹739.9m from 2Q 2024). Profit margin: 4.2% (up from net loss in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance. Announcement • Nov 09
Dishman Carbogen Amcis Limited to Report Q2, 2025 Results on Nov 13, 2024 Dishman Carbogen Amcis Limited announced that they will report Q2, 2025 results on Nov 13, 2024 Announcement • Aug 26
Dishman Carbogen Amcis Limited, Annual General Meeting, Sep 27, 2024 Dishman Carbogen Amcis Limited, Annual General Meeting, Sep 27, 2024, at 15:00 Indian Standard Time. Reported Earnings • Aug 14
First quarter 2025 earnings released: ₹4.95 loss per share (vs ₹1.08 profit in 1Q 2024) First quarter 2025 results: ₹4.95 loss per share (down from ₹1.08 profit in 1Q 2024). Revenue: ₹5.25b (down 27% from 1Q 2024). Net loss: ₹775.7m (down ₹945.7m from profit in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Announcement • Aug 08
Dishman Carbogen Amcis Limited to Report Q1, 2025 Results on Aug 13, 2024 Dishman Carbogen Amcis Limited announced that they will report Q1, 2025 results on Aug 13, 2024 New Risk • Jul 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 62% per year over the past 5 years. Reported Earnings • Jun 04
Full year 2024 earnings released: ₹9.79 loss per share (vs ₹1.90 loss in FY 2023) Full year 2024 results: ₹9.79 loss per share (further deteriorated from ₹1.90 loss in FY 2023). Revenue: ₹26.2b (up 8.4% from FY 2023). Net loss: ₹1.53b (loss widened 415% from FY 2023). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 16
Third quarter 2024 earnings released: ₹3.80 loss per share (vs ₹3.00 profit in 3Q 2023) Third quarter 2024 results: ₹3.80 loss per share (down from ₹3.00 profit in 3Q 2023). Revenue: ₹6.51b (up 1.8% from 3Q 2023). Net loss: ₹596.3m (down 227% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 07
Dishman Carbogen Amcis Limited to Report Q3, 2024 Results on Feb 14, 2024 Dishman Carbogen Amcis Limited announced that they will report Q3, 2024 results on Feb 14, 2024 Reported Earnings • Nov 11
Second quarter 2024 earnings released: ₹2.61 loss per share (vs ₹0.64 loss in 2Q 2023) Second quarter 2024 results: ₹2.61 loss per share (further deteriorated from ₹0.64 loss in 2Q 2023). Revenue: ₹5.87b (down 4.5% from 2Q 2023). Net loss: ₹409.0m (loss widened 307% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 5% per year. Announcement • Sep 05
Dishman Carbogen Amcis Limited to Report Fiscal Year 2024 Results on May 30, 2024 Dishman Carbogen Amcis Limited announced that they will report fiscal year 2024 results on May 30, 2024 Announcement • Aug 24
Dishman Carbogen Amcis Limited, Annual General Meeting, Sep 27, 2023 Dishman Carbogen Amcis Limited, Annual General Meeting, Sep 27, 2023, at 15:00 Indian Standard Time. New Risk • Aug 20
New major risk - Revenue and earnings growth Earnings have declined by 54% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 54% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change). Reported Earnings • Aug 10
First quarter 2024 earnings released: EPS: ₹1.08 (vs ₹0.26 in 1Q 2023) First quarter 2024 results: EPS: ₹1.08 (up from ₹0.26 in 1Q 2023). Revenue: ₹7.30b (up 35% from 1Q 2023). Net income: ₹170.0m (up 324% from 1Q 2023). Profit margin: 2.3% (up from 0.7% in 1Q 2023). Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Aug 03
Dishman Carbogen Amcis Limited to Report Q1, 2024 Results on Aug 09, 2023 Dishman Carbogen Amcis Limited announced that they will report Q1, 2024 results on Aug 09, 2023 Reported Earnings • May 24
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: ₹1.90 loss per share (down from ₹1.15 profit in FY 2022). Revenue: ₹24.4b (up 14% from FY 2022). Net loss: ₹298.0m (down 266% from profit in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Recent Insider Transactions • Feb 18
Global MD & Director recently bought ₹628k worth of stock On the 15th of February, Arpit Vyas bought around 6k shares on-market at roughly ₹99.98 per share. This transaction amounted to 87% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Arpit's only on-market trade for the last 12 months. Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: ₹3.00 (vs ₹2.26 in 3Q 2022) Third quarter 2023 results: EPS: ₹3.00 (up from ₹2.26 in 3Q 2022). Revenue: ₹6.40b (up 14% from 3Q 2022). Net income: ₹469.6m (up 33% from 3Q 2022). Profit margin: 7.3% (up from 6.3% in 3Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Announcement • Feb 04
Dishman Carbogen Amcis Limited to Report Q3, 2023 Results on Feb 10, 2023 Dishman Carbogen Amcis Limited announced that they will report Q3, 2023 results on Feb 10, 2023 Price Target Changed • Nov 16
Price target decreased to ₹168 Down from ₹192, the current price target is an average from 2 analysts. New target price is 58% above last closing price of ₹106. Stock is down 54% over the past year. The company is forecast to post earnings per share of ₹1.80 for next year compared to ₹1.15 last year. Reported Earnings • Nov 16
Second quarter 2023 earnings released: ₹0.64 loss per share (vs ₹0.71 profit in 2Q 2022) Second quarter 2023 results: ₹0.64 loss per share (down from ₹0.71 profit in 2Q 2022). Revenue: ₹6.14b (up 34% from 2Q 2022). Net loss: ₹100.5m (down 190% from profit in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. Independent Director Maitri Mehta was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 13
Second quarter 2023 earnings released: ₹0.64 loss per share (vs ₹0.71 profit in 2Q 2022) Second quarter 2023 results: ₹0.64 loss per share (down from ₹0.71 profit in 2Q 2022). Revenue: ₹6.23b (up 36% from 2Q 2022). Net loss: ₹100.5m (down 190% from profit in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 10
First quarter 2023 earnings released: EPS: ₹0.26 (vs ₹1.02 in 1Q 2022) First quarter 2023 results: EPS: ₹0.26 (down from ₹1.02 in 1Q 2022). Revenue: ₹5.46b (flat on 1Q 2022). Net income: ₹40.1m (down 75% from 1Q 2022). Profit margin: 0.7% (down from 2.9% in 1Q 2022). Over the next year, revenue is forecast to grow 17%, compared to a 38% growth forecast for the industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. Price Target Changed • May 12
Price target decreased to ₹213 Down from ₹252, the current price target is provided by 1 analyst. New target price is 84% above last closing price of ₹116. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₹7.00 for next year compared to ₹1.15 last year. Reported Earnings • May 11
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: ₹1.15 (up from ₹10.53 loss in FY 2021). Revenue: ₹21.8b (up 14% from FY 2021). Net income: ₹180.1m (up ₹1.83b from FY 2021). Profit margin: 0.8% (up from net loss in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 83%. Over the next year, revenue is forecast to grow 9.5%, compared to a 37% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 2 highly experienced directors. Independent Director Maitri Mehta was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Feb 05
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: ₹2.26 (up from ₹1.02 loss in 3Q 2021). Revenue: ₹5.81b (up 24% from 3Q 2021). Net income: ₹353.8m (up ₹514.5m from 3Q 2021). Profit margin: 6.1% (up from net loss in 3Q 2021). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates. Over the next year, revenue is forecast to grow 13%, compared to a 34% growth forecast for the industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance. Board Change • Dec 06
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. Independent Director Maitri Mehta was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 29
Second quarter 2022 earnings released: EPS ₹0.71 (vs ₹0.47 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹4.69b (up 6.6% from 2Q 2021). Net income: ₹111.9m (up 52% from 2Q 2021). Profit margin: 2.4% (up from 1.7% in 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Price Target Changed • Oct 28
Price target decreased to ₹239 Down from ₹261, the current price target is provided by 1 analyst. New target price is 13% above last closing price of ₹210. Stock is up 35% over the past year. The company is forecast to post earnings per share of ₹6.30 next year compared to a net loss per share of ₹10.53 last year. Reported Earnings • Aug 18
First quarter 2022 earnings released: EPS ₹1.02 (vs ₹1.37 loss in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹5.51b (up 16% from 1Q 2021). Net income: ₹160.2m (up ₹374.5m from 1Q 2021). Profit margin: 2.9% (up from net loss in 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 29
Full year 2021 earnings released: ₹10.53 loss per share (vs ₹9.85 profit in FY 2020) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: ₹19.1b (down 6.4% from FY 2020). Net loss: ₹1.65b (down 204% from profit in FY 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Reported Earnings • May 14
Full year 2021 earnings released: ₹10.53 loss per share (vs ₹11.20 profit in FY 2020) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: ₹19.5b (down 4.7% from FY 2020). Net loss: ₹1.65b (down 192% from profit in FY 2020). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • May 07
Investor sentiment improved over the past week After last week's 17% share price gain to ₹184, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 55x in the Life Sciences industry in Asia. Total loss to shareholders of 47% over the past three years. Valuation Update With 7 Day Price Move • Apr 19
Investor sentiment improved over the past week After last week's 19% share price gain to ₹132, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 52x in the Life Sciences industry in Asia. Total loss to shareholders of 61% over the past three years. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment improved over the past week After last week's 15% share price gain to ₹136, the stock is trading at a trailing P/E ratio of 44.5x, up from the previous P/E ratio of 38.7x. This compares to an average P/E of 45x in the Life Sciences industry in India. Total return to shareholders over the past three years is a loss of 56%. Is New 90 Day High Low • Feb 26
New 90-day low: ₹118 The company is down 19% from its price of ₹145 on 27 November 2020. The Indian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 3.0% over the same period. Reported Earnings • Feb 14
Third quarter 2021 earnings released: ₹1.02 loss per share (vs ₹2.04 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹4.69b (down 14% from 3Q 2020). Net loss: ₹160.7m (down 149% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. Analyst Estimate Surprise Post Earnings • Feb 14
Revenue and earnings miss expectations Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 14%. Over the next year, revenue is forecast to grow 13%, compared to a 35% growth forecast for the Life Sciences industry in India. Is New 90 Day High Low • Jan 27
New 90-day low: ₹131 The company is down 16% from its price of ₹156 on 29 October 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 12% over the same period. Valuation Update With 7 Day Price Move • Dec 08
Market bids up stock over the past week After last week's 16% share price gain to ₹163, the stock is trading at a trailing P/E ratio of 28.1x, up from the previous P/E ratio of 24.2x. This compares to an average P/E of 35x in the Life Sciences industry in India. Total return to shareholders over the past three years is a loss of 45%. Is New 90 Day High Low • Nov 03
New 90-day low: ₹138 The company is down 33% from its price of ₹207 on 05 August 2020. The Indian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹55.48 per share.